Angelini and APR Applied Pharma Research strengthen their partnership in wound care with the launch of Nexodyn in the USA.
The new Nexodyn AOS wound care solution, cleared for sale by the FDA, is now starting to be available in the USA, promoted and commercialized by the Italian pharmaceutical company Angelini, as a result of an exclusive partnership with the Swiss company APR Applied Pharma Research, the owner and developer of the proprietary, patented technology TEHCLO, for the production of acidic super-oxidizing solutions.
Nexodyn helps cleanse and moisten the wound environment by removing dirt, debris and foreign material by flushing across the wound. Nexodyn is intended for use, under the supervision of healthcare professionals, to treat acute and chronic dermal lesions (such as leg ulcers, post-surgical wounds or 1st and 2nd degree burns) and minor cuts, burns, skin irritations and superficial abrasions.
The solution, characterized by an acidic pH between 2.5 and 3.0, has cell viability preservation features, so as not to negatively interfere with the natural physiological healing process and epthelialization. Its antimicrobial preservative effectiveness has been demonstrated by in vitro testing against P. aeruginosa, E. coli, S. aureus, S. epidermidis, S. pyogenes, E. gergoviae, C. albicans and A. niger, according to the companies.
APR is a Swiss, independent developer of science driven, patent protected healthcare products. www.apr.ch.
Angelini is a privately-held, mid-sized international manufacturer and marketer of pharmaceutical and healthcare products in the pharmaceutical and mass-market sectors. www.angelinipharma.com.
(Source: Business Wire)
